Safety of reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from six trials

ConclusionsThis analysis confirms that treatment with intravenous reslizumab for>12 months is well tolerated in patients with asthma, with no evidence of rare safety events that were not detected in individual trials.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research